scholarly journals Effect of Vitamin C Supplementation on C-reactive Protein Levels in Patients Undergoing Hemodialysis: A Randomized, Double Blind, Placebo-Controlled Study

2013 ◽  
Vol 6 (1) ◽  
Author(s):  
Vajihe Biniaz ◽  
Mehdi Sadeghi Shermeh ◽  
Abbas Ebadi ◽  
Ali Tayebi ◽  
Behzad Einollahi
Keyword(s):  
Vitamin C ◽  
Controlled Study ◽  
C Reactive Protein ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Protein Levels ◽  
Reactive Protein ◽  
Vitamin C Supplementation

Abstract 874: MLN1202, a Novel CCR2 Antagonist, Decreases C-reactive protein in Patients at Risk for Atherosclerotic Cardiovascular Disease in a Double Blind Placebo Controlled study

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
M. Davidson ◽  
J. Lekstrom-Himes ◽  
J. Gilbert ◽  
D. Donaldson ◽  
Y. Lee ◽  
...  
Keyword(s):  
At Risk ◽  
Lipid Lowering ◽  
Smoking History ◽  
Controlled Study ◽  
C Reactive Protein ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Reactive Protein ◽  
Patients At Risk ◽  
Circulating Levels

Background: Macrophages play a central role in atherosclerotic plaque formation. The CC chemokine receptor 2 (CCR2), expressed on the surface of circulating monocytes, and its ligand MCP-1 (CCL2), are present in atherosclerotic plaques and may play a critical part in endothelial monocyte recruitment and activation. MLN1202 is a humanized monoclonal antibody with high specificity to CCR2, which interrupts MCP-1 binding to CCR2. MLN1202 is being developed for the treatment of immune mediated diseases. Hypothesis: We tested the hypothesis that MLN1202 significantly influences disease activity in patients at risk for ASCVD as measured by a reduction in circulating levels of high sensitivity C-reactive protein (hsCRP), an established biomarker of inflammation. Trial Design: In this double-blind placebo controlled study patients with at least 2 or more risk factors for ASCVD, no history or symptoms of ASCVD disease, and circulating levels of hsCRP > 3mg/L, were randomized 1:1 to receive a single infusion of 10 mg/kg MLN1202 (n 56) or placebo (n = 56). Subjects with hypercholesterolemia on stable doses of lipid-lowering agents were included. Circulating levels of hsCRP were determined every 2 weeks, and clinical examination performed every 4 weeks for 16 weeks following treatment. Results and Conclusion: Patients were recruited from nine centers in the US. The study population had a mean age of 60.9 years and included subjects with hypertension (59%), hypercholesterolemia (70%), significant smoking history (28%), and type 2 diabetes (16%). At screening the median value CRP was 6.8 mg/L with interquartile range from 4.7–9.3 mg/L. PK/PD results showed that the plasma level of MLN1202 required for > 90% receptor saturation was maintained for 6 to 8 weeks. A between-group difference in reduction of hsCRP was statistically significant from week 4 through week 8 following dosing. The maximum difference in absolute median reduction was observed at week 8 and it was 1.6 mg/L (p = 0.0275; Wilcoxon); the observed median percent reduction of hsCRP was 24.2% for MLN1202 group versus 2.5% increase for placebo group at 8 weeks (p = 0.0089; Wilcoxon). These data indicate that blockade of CCR2 reduces a biomarker related to inflammation in patients at risk for ASCVD.

scholarly journals Intravenous Lidocaine for Effective Pain Relief After a Laparoscopic Colectomy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

2015 ◽  
Vol 100 (3) ◽  
pp. 394-401 ◽  
Author(s):  
EunJin Ahn ◽  
Hyun Kang ◽  
Geun Joo Choi ◽  
Yong Hee Park ◽  
So Young Yang ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Laparoscopic Colectomy ◽  
Controlled Study ◽  
Intravenous Lidocaine ◽  
C Reactive Protein ◽  
Double Blind ◽  
Reactive Protein ◽  
Fentanyl Consumption ◽  
Vas Scores ◽  
Effective Pain Relief

A perioperative intravenous lidocaine infusion has been reported to decrease postoperative pain. The goal of this study was to evaluate the effectiveness of intravenous lidocaine in reducing postoperative pain for laparoscopic colectomy patients. Fifty-five patients scheduled for an elective laparoscopic colectomy were randomly assigned to 2 groups. Group L received an intravenous bolus injection of lidocaine 1.5 mg/kg before intubation, followed by 2 mg/kg/h continuous infusion during the operation. Group C received the same dosage of saline at the same time. Postoperative pain was assessed at 2, 4, 8, 12, 24, and 48 hours after surgery by using the visual analog scale (VAS). Fentanyl consumption by patient-controlled plus investigator-controlled rescue administration and the total number of button pushes were measured at 2, 4, 8, 12, 24, and 48 hours after surgery. In addition, C-reactive protein (CRP) levels were checked on the operation day and postoperative days 1, 2, 3, and 5. VAS scores were significantly lower in group L than group C until 24 hours after surgery. Fentanyl consumption was lower in group L than group C until 12 hours after surgery. Moreover, additional fentanyl injections and the total number of button pushes appeared to be lower in group L than group C (P < 0.05). The CRP level tended to be lower in group L than group C, especially on postoperative day1 and 2 and appeared to be statistically significant. The satisfaction score was higher in group L than group C (P = 0.024). Intravenous lidocaine infusion during an operation reduces pain after a laparoscopic colectomy.

Vitamin C supplementation and C-reactive protein levels: Findings from a systematic review and meta-analysis of clinical trials

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Maryam Safabakhsh ◽  
Mohammad Reza Emami ◽  
Mohammad Zeinali Khosroshahi ◽  
Omid Asbaghi ◽  
Shaghayegh Khodayari ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Vitamin C ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Subgroup Analyses ◽  
Vitamin C Supplementation ◽  
Hs Crp

AbstractBackground and purposeC-reactive protein (CRP) is an inflammatory biomarker which prognosticates cardiovascular disease. Previous studies have reached mixed conclusions regarding the effect of vitamin C on reducing CRP or hs-CRP level. The present systematic review and meta-analysis was conducted to resolve these inconsistencies.Materials and methods: Related articles published up to August 2018 were searched through PubMed, Scopus, Ovid, ISI web of science, Embase, and Cochrane databases by relevant keywords. Clinical trials which examined the effect of either vitamin C supplementation or vitamin C-enriched foods on CRP and hs-CRP levels were included. A total of 11 studies with 14 data sets involving 818 subjects were included.ResultsOverall, the pooled analysis revealed that vitamin C could decrease CRP level relative to placebo group (Weighted mean difference [WMD]=−0.73 mg/L: 95% CI: −1.30 to −0.15, p=0.013) with a considerable heterogeneity (I2=98%, p<0.001). Moreover, subgroup analyses revealed that the beneficial effect of vitamin C on CRP level alternation only was found in male (p=0.003), non-smoker (p=0.041), healthy (p=0.029) and younger participants (p=0.010). Vitamin C could improve CRP level only at doses of less than 500 mg/day (p=0.009). Regarding hs-CRP changes, the pooled analysis did not show any significant effect of vitamin C (WMD=−0.65 mg/L: 95% CI: −2.03 to 0.72, p=0.35). This finding was confirmed by all subgroup analyses expect for high quality articles in which hs-CRP level was elevated after vitamin C supplementation (p=0.026).ConclusionIn conclusion, supplementation with vitamin C might have a significant effect only on CRP reduction. Further studies are needed to confirm this effect.

Sign in / Sign up

Export Citation Format

Share Document